Immunotherapy for non-small cell lung cancers: Biomarkers for predicting responses and strategies to overcome resistance

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: A phase II efficacy and biomarker study

13 p | 7 | 3

A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: Real-world practice

14 p | 3 | 2

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression≥50%

12 p | 4 | 2

Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: A retrospective analysis from the I-O Optimise initiative

13 p | 11 | 2

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer

18 p | 11 | 1

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: Younger versus older adults

11 p | 2 | 1

Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitorrelated pneumonitis

9 p | 10 | 0